Drug intelligence / Profile preview

VSF1.01

Development stage: Phase 2
Modality: Cell Therapies
Administration: Intracochlear

Overview

VSF1.01 is an investigational solution for injection derived from the conditioned medium of adult human umbilical tissue, designed for intracochlear application to reduce surgery-related trauma in patients undergoing cochlear implantation for profound hearing loss. The drug is administered as an adjuvant treatment during cochlear implant surgery, prior to insertion of the electrode array, with the primary objective of improving safety and potentially reducing trauma associated with the procedure[1][2]. The precise mechanism of action has not been fully elucidated but is presumed to involve modulation of local tissue response and inflammation due to factors present in the conditioned medium.

Brand names: VSF1.01VSF-1.01VSF 1.01
Other names: VSF1.01VSF-1.01VSF 1.01

Beyond the preview

Go deeper on VSF1.01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VSF1.01.

Explore the full profile